Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1‐based therapy-Reference-Cited by-同舟云学术

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1‐based therapy

Published:2018-12-06 Issue:6 Volume:125 Page:884-891
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Saab Karim R.¹²,Mooradian Meghan J.³,Wang Daniel Y.⁴,Chon Jeewon⁴,Xia Cathy Y.⁵,Bialczak Angelica¹,Abbate Kelly T.¹,Menzies Alexander M.⁵⁶,Johnson Douglas B.⁴^ORCID,Sullivan Ryan J.³,Shoushtari Alexander N.¹²^ORCID

Affiliation:

1. Department of Medicine Memorial Sloan Kettering Cancer Center New York New York

2. Department of Medicine Weill Cornell Medical College New York New York

3. Department of Medicine Massachusetts General Hospital Cancer Center Boston Massachusetts

4. Department of Medicine Vanderbilt University Medical Center Nashville Tennessee

5. Department of Medicine Melanoma Institute Australia Sydney New South Wales Australia

6. The University of Sydney Sydney New South Wales Australia

Funder

Memorial Sloan Kettering Cancer Center Core

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.31889

Reference25 articles.

1. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

2. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

3. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

4. Pembrolizumab versus Ipilimumab in Advanced Melanoma

5. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature;Cancer Treatment Reviews;2024-09

2. Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy;European Journal of Cancer;2024-03

3. Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAF^V600/NRAS^Q61 Wild-Type Melanoma (TraMel-WT);JCO Precision Oncology;2024-02

4. Metabolic Profiling to Assess Response to Targeted and Immune Therapy in Melanoma;International Journal of Molecular Sciences;2024-01-31

5. POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis;Neuro-Oncology Advances;2024-01-01